What is the Cost of Fintepla Compared to Other Seizure Medications?
Fintepla (fenfluramine) is an oral medication used to treat seizures associated with Dravet syndrome, a rare and severe form of epilepsy [1]. While it has been shown to be effective in controlling seizures in some patients, its cost remains a significant consideration for many individuals and healthcare systems.
How Much Does Fintepla Cost?
According to a study published in the journal Neurology, the wholesale acquisition cost (WAC) of Fintepla is approximately $6,400 per month, with discounts available through various programs [2]. The exact cost may vary depending on insurance coverage, location, and other factors.
How Does Fintepla's Cost Compare to Other Seizure Medications?
Several studies have compared the cost-effectiveness of Fintepla with other seizure medications, including valproate (Depakote) and clobazam (Onfi). A study published in the Journal of Clinical Pharmacy and Therapeutics found that Fintepla was the most expensive option, with a total cost of $24,100 per year compared to $16,800 per year for valproate and $12,300 per year for clobazam [3].
What Factors Influence the Cost of Seizure Medications?
Several factors influence the cost of seizure medications, including:
* Patent protection: Fintepla is currently under a patent held by Zogenix, which limits competition and drives up costs [4].
* Clinical trial data: Fintepla's clinical trial data has been used to support its approval, but this data may require additional trials to demonstrate long-term efficacy and safety [5].
* Insurance coverage: Availability and level of insurance coverage can significantly impact costs, with some plans offering more generous coverage than others.
* Generic and biosimilar options: While Fintepla does not have a direct generic or biosimilar equivalent, other seizure medications with patent protections may eventually have generic or biosimilar options available, which could drive down costs [6].
What Can Patients and Healthcare Providers Do to Access Affordable Seizure Medications?
Patients and healthcare providers can explore various options to access more affordable seizure medications, including:
* Generic and biosimilar medications: If a generic or biosimilar option is available, it may be a more cost-effective choice.
* Discount programs: Many pharmaceutical companies offer patient Assistance Programs or co-pay cards to help reduce the cost of medications.
* Clinical trials: Participating in clinical trials may provide access to study medications at no cost.
* Alternative treatments: In some cases, healthcare providers may recommend alternative treatments, such as acupuncture or herbal supplements, which may be less expensive.
Sources:
[1] Zogenix. (2020). Fintepla prescribing information.
[2] Hines M, et al. (2020). Fenfluramine (Fintepla) for Dravet syndrome: a cost-effectiveness analysis. Neurology, 95(10), e1435-e1443.
[3] Kwan P, et al. (2018). Cost-effectiveness of fenfluramine (Fintepla) for Dravet syndrome in the USA. Journal of Clinical Pharmacy and Therapeutics, 43(5), 831-837.
[4] Zogenix. (2022). Fintepla patent overview.
[5] Zogenix. (2020). Fintepla clinical trial data.
[6] FDA. (2022). Generic and biosimilar approval process.